Crossmark

The Design and Rationale of a Phase 2b, Randomized, Double-Blinded, and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Lomecel-B in Older Adults with Frailty

Crossref DOI link: https://doi.org/10.14283/jfa.2022.2

Published Print: 2022-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Yousefi, K.

Ramdas, K.N.

Ruiz, J.G.

Walston, J.

Arai, H.

Volpi, E.

Newman, A.B.

Wang, C.

Hitchinson, B.

McClain-Moss, L.

Diaz, L.

Green, G.A.

Hare, J.M.

Oliva, Anthony A.
License Information

Text and Data Mining valid from 2022-04-01

Text and Data Mining valid from 2022-04-01

Version of Record valid from 2022-01-04
More Information

This article is maintained by: Elsevier

Article Title: The Design and Rationale of a Phase 2b, Randomized, Double-Blinded, and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Lomecel-B in Older Adults with Frailty

Journal Title: The Journal of Frailty & Aging

CrossRef DOI link to publisher maintained version: https://doi.org/10.14283/jfa.2022.2

Content Type: article

Copyright: Copyright © 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS

Document is current

Any future updates will be listed below